Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor

 Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor

Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor

Shots:

  • The P-II KINETIC study involves assessing the efficacy, safety, and tolerability of SAGE-324 (60mg, qd) vs PBO in 69 patients in a ratio (1:1) aged 18-80yrs. with essential tremor for 29 days
  • The study met its 1EPs i.e reduction from baseline in TETRAS Performance Subscale Item 4 upper limb tremor score @29day (36% vs 21%), ADL score is numerically superior at all time points, consistent safety profile with previously reported data
  • In a more severe population, a reduction from baseline in tetras Upper Limb Item 4 >12, SAGE-32 demonstrated a (41% vs 18%) reduction from baseline in upper limb tremor amplitude

Click here to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post